Spexis AG (SIX:SPEX) is a clinical-stage biotech company focused on first-in-class macrocyclic drugs for cancer & rare diseases. >25 years and $400M of R & D has resulted in three clinical candidates (Ph1-2) & preclinical macrocycle drug conjugates (MDCs) and macrocycle radio-conjugates (MRCs).
Cooperation possibilities
We seek corporate partners & investors for our Ph1b/2a balixafortide clinical program in pancreatic ductal adenocarcinoma (“PDAC”), our MDC/MRC platform, and for our P2-ready lonodelestat and murepavidin programs. These programs possess abundant clinical and pre-clinical data.
- https://www.spexisbio.com/
- +41 61 567 16 00
- info@spexisbio.com
- Jeff Wager, MD, Chair & CEO
